TW201408299A - 不含鹼化劑之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）調配物 - Google Patents
不含鹼化劑之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）調配物 Download PDFInfo
- Publication number
- TW201408299A TW201408299A TW102124610A TW102124610A TW201408299A TW 201408299 A TW201408299 A TW 201408299A TW 102124610 A TW102124610 A TW 102124610A TW 102124610 A TW102124610 A TW 102124610A TW 201408299 A TW201408299 A TW 201408299A
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- stable pharmaceutical
- laquinimod
- composition according
- filler
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261670268P | 2012-07-11 | 2012-07-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201408299A true TW201408299A (zh) | 2014-03-01 |
Family
ID=49914501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW102124610A TW201408299A (zh) | 2012-07-11 | 2013-07-09 | 不含鹼化劑之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）調配物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140018386A1 (https=) |
| EP (1) | EP2872141A4 (https=) |
| JP (1) | JP2015527321A (https=) |
| KR (1) | KR20150036553A (https=) |
| CN (1) | CN104470519A (https=) |
| AR (1) | AR091706A1 (https=) |
| AU (1) | AU2013290274A1 (https=) |
| BR (1) | BR112015000321A2 (https=) |
| CA (1) | CA2873230A1 (https=) |
| EA (1) | EA201590193A1 (https=) |
| HK (1) | HK1209054A1 (https=) |
| IL (1) | IL236229A0 (https=) |
| MX (1) | MX2015000398A (https=) |
| NZ (1) | NZ630241A (https=) |
| SG (2) | SG10201700198VA (https=) |
| TW (1) | TW201408299A (https=) |
| UA (1) | UA115555C2 (https=) |
| WO (1) | WO2014011750A1 (https=) |
| ZA (1) | ZA201500287B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2445451T3 (es) | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| CN106063787A (zh) | 2012-02-03 | 2016-11-02 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| JP2015535287A (ja) | 2012-11-07 | 2015-12-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドのアミン塩 |
| NZ630427A (en) | 2013-03-14 | 2017-06-30 | Teva Pharma | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| EA201692180A1 (ru) | 2014-04-29 | 2017-08-31 | Тева Фармасьютикал Индастриз Лтд. | Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации |
| CN107823168A (zh) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | 一种快速溶解的片剂及其制备方法 |
| CN107823150A (zh) * | 2017-10-25 | 2018-03-23 | 北京素维生物科技有限公司 | 一种可快速分散的片剂及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0001621D0 (en) * | 2000-01-26 | 2000-03-15 | Astrazeneca Ab | Pharmaceutical compositions |
| SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| US7884208B2 (en) * | 2005-10-19 | 2011-02-08 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
| RS52169B (sr) * | 2006-06-12 | 2012-08-31 | Teva Pharmaceutical Industries Limited | Stabilni preparati lakvinimoda |
| ES2445451T3 (es) * | 2007-12-20 | 2014-03-03 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
| WO2010070449A2 (en) * | 2008-12-17 | 2010-06-24 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| WO2013016686A1 (en) * | 2011-07-28 | 2013-01-31 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
-
2013
- 2013-07-08 AR ARP130102429 patent/AR091706A1/es unknown
- 2013-07-09 TW TW102124610A patent/TW201408299A/zh unknown
- 2013-07-10 SG SG10201700198VA patent/SG10201700198VA/en unknown
- 2013-07-10 EA EA201590193A patent/EA201590193A1/ru unknown
- 2013-07-10 KR KR1020157003693A patent/KR20150036553A/ko not_active Withdrawn
- 2013-07-10 EP EP13816725.9A patent/EP2872141A4/en not_active Withdrawn
- 2013-07-10 BR BR112015000321A patent/BR112015000321A2/pt active Search and Examination
- 2013-07-10 MX MX2015000398A patent/MX2015000398A/es unknown
- 2013-07-10 HK HK15109818.4A patent/HK1209054A1/xx unknown
- 2013-07-10 JP JP2015521771A patent/JP2015527321A/ja active Pending
- 2013-07-10 AU AU2013290274A patent/AU2013290274A1/en not_active Abandoned
- 2013-07-10 CN CN201380027660.2A patent/CN104470519A/zh active Pending
- 2013-07-10 NZ NZ630241A patent/NZ630241A/en not_active IP Right Cessation
- 2013-07-10 SG SG11201407688QA patent/SG11201407688QA/en unknown
- 2013-07-10 WO PCT/US2013/049894 patent/WO2014011750A1/en not_active Ceased
- 2013-07-10 CA CA2873230A patent/CA2873230A1/en not_active Abandoned
- 2013-07-10 US US13/938,733 patent/US20140018386A1/en not_active Abandoned
- 2013-10-07 UA UAA201413984A patent/UA115555C2/uk unknown
-
2014
- 2014-12-14 IL IL236229A patent/IL236229A0/en unknown
-
2015
- 2015-01-15 ZA ZA2015/00287A patent/ZA201500287B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ630241A (en) | 2017-09-29 |
| ZA201500287B (en) | 2016-10-26 |
| EA201590193A1 (ru) | 2015-04-30 |
| IL236229A0 (en) | 2015-01-29 |
| US20140018386A1 (en) | 2014-01-16 |
| EP2872141A4 (en) | 2016-01-13 |
| BR112015000321A2 (pt) | 2017-06-27 |
| SG11201407688QA (en) | 2014-12-30 |
| WO2014011750A1 (en) | 2014-01-16 |
| JP2015527321A (ja) | 2015-09-17 |
| EP2872141A1 (en) | 2015-05-20 |
| HK1209054A1 (zh) | 2016-03-24 |
| AR091706A1 (es) | 2015-02-25 |
| WO2014011750A8 (en) | 2014-12-04 |
| MX2015000398A (es) | 2015-04-10 |
| SG10201700198VA (en) | 2017-02-27 |
| AU2013290274A1 (en) | 2014-11-27 |
| KR20150036553A (ko) | 2015-04-07 |
| UA115555C2 (uk) | 2017-11-27 |
| CN104470519A (zh) | 2015-03-25 |
| CA2873230A1 (en) | 2014-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201408299A (zh) | 不含鹼化劑之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）調配物 | |
| CN104902958A (zh) | 用于治疗神经退行性疾病的拉喹莫德和普利多匹定 | |
| ES3040117T3 (en) | Formulations of a somatostatin modulator | |
| AU2022331317B2 (en) | IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS | |
| CA2984615C (en) | Vortioxetine pyroglutamate | |
| CN102958514B (zh) | 口腔内崩解片剂 | |
| EP2514422B1 (en) | Elution stabilized teneligliptin preparation | |
| TW201713343A (zh) | 經口投與用醫藥組成物 | |
| BR112020019425A2 (pt) | Composição farmacêutica compreendendo meta-arsenito e método de fabricação | |
| CN114716417B (zh) | 化合物与富马酸的结晶形式的原料药及其药物组合物和用途 | |
| RU2462248C2 (ru) | Стабильная фармацевтическая композиция, содержащая водорастворимую соль винфлунина | |
| ES2450944T3 (es) | Composición y comprimido que comprenden raltegravir | |
| CN102137664A (zh) | 具有被边界隔开的有效成分的固体药物制剂 | |
| CA2835912A1 (en) | Pharmaceutical composition comprising fexofenadine | |
| JP2021505531A (ja) | 医薬組成物 | |
| JP2019515045A (ja) | 甲状腺ホルモン又はそのアナログを提供する組成物及び方法 | |
| EP3162368A1 (en) | Pharmaceutical composition for oral administration | |
| EP2320874A1 (en) | Solid pharmaceutical composition comprising exemestane | |
| WO2007049626A1 (ja) | カベルゴリン含有経口固形製剤 | |
| JP2006104194A (ja) | 用時調製型レバミピド注腸製剤 | |
| TW201414476A (zh) | 經改善溶出性及／或吸收性之經口投予用醫藥組成物 | |
| CN108186589A (zh) | 一种阿折地平组合物 | |
| JP2004091373A (ja) | 分解に対する安定性及び含量均一性に優れたメシル酸ペルゴリド含有製剤 | |
| JPWO2016121664A1 (ja) | ピロールカルボキサミドの固形組成物 | |
| CN109475605A (zh) | 提供甲状腺激素或其类似物的组合物和方法 |